Serum Insulin‐like Growth Factors, Insulin‐like Growth Factor‐binding Protein‐3, and Risk of Lung Cancer Death: A Case‐control Study Nested in the Japan Collaborative Cohort (JACC) Study

Wakai, Kenji; Ito, Yoshinori; Suzuki, Kôji; Tamakoshi, Akiko; Seki, Nao; Ando, Masahiko; Ozasa, Kotaro; Watanabe, Yoshiyuki; Kondo, Takaaki; Nishino, Yoshikazu; Ohno, Yoshiyuki

doi:10.1111/j.1349-7006.2002.tb01235.x

Cited by 42 publications

(32 citation statements)

References 30 publications

(54 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Prostate cancer, a malignancy of older men, is reported to decrease with duration of diabetes (13,29); however, the reverse trend has also been reported (30). Alternatively, as the diabetes-cancer relationship is not fully understood, any association may vary with tumor type (9,31).…”

Section: Resultsmentioning

confidence: 76%

Diabetes and the Risk of Lung Cancer

Hall¹,

Roberts

Boulis

et al. 2005

Diabetes Care

View full text Add to dashboard Cite

OBJECTIVE -The incidence of some cancers has been reported to be higher in diabetic patients than in the general population. We estimated the incidence of lung cancer in diabetic patients and investigated the hypothesis that the rate of lung cancer is different in diabetic compared with nondiabetic patients.RESEARCH DESIGN AND METHODS -Diabetic patients and age-, sex-, and general practice-matched nondiabetic control subjects were identified from U.K. computerized general practice records (General Practice Research Database), and these records searched for any incident lung cancer, demographic details, and smoking status. Primary lung cancer incidence was calculated and rates compared between diabetic patients and nondiabetic control subjects using multivariate Cox regression, adjusting for age, sex, and smoking. The comparison was repeated for incident diabetic patients followed from diagnosis and after stratifying by diabetic treatment.RESULTS -The incidence of primary lung cancer in all 66,848 diabetic patients was 1.63 per 1,000 patient-years (95% CI 1.48 -1.79) and 2.05 per 1,000 patient-years (1.76 -2.38) among diabetic patients followed from diagnosis. When compared with nondiabetic control subjects, the hazard ratio was 0.88 (0.79 -0.97) for all diabetic patients and 1.12 (0.95-1.34) for those followed from diagnosis. When observation was truncated to allow for shorter life expectancy, the hazard ratio for the total cohort was 0.98 (0.84 -1.13), and no association was found with any treatment group.CONCLUSIONS -No increased risk of lung cancer in diabetes was found. We hypothesize that the lower incidence may be partly due to shorter life expectancy. Diabetes Care 28:590 -594, 2005

show abstract

Section: Resultsmentioning

confidence: 76%

Diabetes and the Risk of Lung Cancer

Hall¹,

Roberts

Boulis

et al. 2005

Diabetes Care

View full text Add to dashboard Cite

show abstract

“…Table 3 and Figure 1 shows the meta-analysis of IGF-1, IGF-2 and IGFBP-3 results from published prospective studies and the results from the present study (there were no published studies on IGF-2 and lung cancer). This analysis includes all the studies in the earlier analysis by Renehan et al (2004) together with eight others (Lacey et al, 2001;Wakai et al, 2002;Nomura et al, 2003;Woodson et al, 2003;Stattin et al, 2004;Chen et al, 2005;Meyer et al, 2005;Platz et al, 2005). The meta-analysis was restricted to data from prospective studies to minimise any effects of the cancer on the measurements made.…”

Section: Resultsmentioning

confidence: 99%

Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies

Morris

George

et al. 2006

Br J Cancer

View full text Add to dashboard Cite

Insulin-like growth factor-1 (IGF-1), insulin-like growth factor-2 (IGF-2), and insulin-like growth factor binding protein-3 (IGFBP-3) were measured in frozen serum samples from 1051 men with cancer and 3142 controls in a nested case -control study from the British United Provident Association (BUPA) study cohort and associations with 14 cancers were examined, including prostate, colorectal, and lung. A meta-analysis of studies on these three cancer sites was also conducted. In the meta-analysis the odds ratio between the highest quartile IGF-1 group and the lowest quartile group was 1.31 (95% confidence interval (CI): 1.03 -1.67) for prostate, 1.37 (1.05 -1.78) for colorectal and 1.02 (0.80 -1.31) for lung cancer, and for IGF-2 it was 0.72 (0.36 -1.44) for prostate and 1.95 (1.26 -3.00) for colorectal cancer. Results from the BUPA study were consistent with the estimates from the other studies. There were no statistically significant associations with IGFBP-3 and any of the cancer sites considered. Our results suggest that IGF-1, IGF-2, and IGFBP-3 measurements have no value in cancer screening, although IGF-1 and IGF-2 may be of aetiological significance in relation to colorectal and prostate cancer. Prospective studies have shown that higher circulating concentrations of insulin-like growth factor 1 (IGF-1), insulin-like growth factor 2 (IGF-2), and insulin-like growth factor binding protein-3 (IGFBP-3) are associated with an increased risk of prostate cancer, colorectal cancer, and premenopausal breast, and ovarian cancer Renehan et al, 2004). Aetiological importance has been attributed to these associations, and it has been suggested that they may be of value in screening for these cancers.We here report results on measurements of IGF-1, IGF-2, and IGFBP-3 from the British United Provident Association (BUPA) prospective study, based on 1051 new cases of cancer at 14 different cancer sites, and we combine the results on prostate, colorectal, and lung cancer with those from published studies in a meta-analysis. METHODSThe BUPA study is a prospective study of 21 520 professional men aged 35 -64 years resident in Britain who attended the BUPA medical centre in London between 1975 and 1982 for a routine medical examination. Serum samples were stored at À401C. The men were flagged at the National Health Service Central Register in Southport, permitting automatic notification of death (with the certified cause) and cancer incidence by the Office for National Statistics. Further information on the causes of death was obtained by writing to each certifying doctor. This analysis is based on a maximum follow-up of 15 years and is restricted to those cancers for which at least 10 cases occurred. In this period, there were 1059 men for whom we had a cancer notification. For each case, three controls (who were still alive and for whom we did not have a cancer notification) were selected; they were matched for age and duration of storage of the serum sample each to one year.In 2003 the frozen serum samples were retrieved....

show abstract

“…For example, Yu et al (1999) reported that high plasma levels of IGF-I were associated with a 2-fold increase in the OR (OR = 2.06; 95% CI 1.19-3.56; P = 0.01) of developing lung cancer, whereas increased levels of IGFBP-3 were associated with a 50% reduction (OR = 0.48; 95% CI 0.25-0.92; P = 0.03), after adjustment for IGF-I levels. In a large casecontrol study nested within the Japan Collaborative Cohort Study, subjects in the highest quartile of circulating IGFBP-3 showed a reduced OR for developing lung cancer compared with those in the lowest quartile (OR = 0.55; 95% CI 0.37-0.81; P = 0.04; Wakai et al 2002). In addition, after adjusting for IGFBP-3 levels, this risk was increased in the highest vs the lowest quartile of IGF-I (OR = 1.74; 95% CI 1.08-2.81).…”

Section: Lung Cancermentioning

confidence: 99%

Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions.

Jerome¹,

Shiry²,

Leyland‐Jones³

2003

Endocrine-Related Cancer

View full text Add to dashboard Cite

The IGF system performs a fundamental role in the regulation of cellular proliferation, differentiation and apoptosis. These diverse biological actions are mediated primarily by IGF association with the type I IGF receptor (IGF-IR), which is in turn regulated by a group of high-affinity IGF-binding proteins (IGFBP-1 to -6). All of the IGFBPs can have growth-inhibitory effects by competitively binding IGFs and preventing their association with the IGF-IR. IGFBP-3 is the most abundant binding protein in the circulation and controls the actions of the IGFs by regulating their distribution and bioavailability to target tissues. Disruptions in the balance of IGF system components leading to excessive proliferation and survival signals have been implicated in the development of different tumor types. Epidemiological evidence indicates that increased levels of IGF-I, reduced levels of IGFBP-3 or an increased ratio of IGF-I to IGFBP-3 in the circulation are associated with an increased risk for the development of several common cancers, including those of the breast, prostate, lung and colon. The results of preclinical studies indicate that a diversity of interventions which antagonize IGF-IR signaling or augment IGFBP-3 function inhibit tumor cell growth in models of human cancers. A more comprehensive understanding of the interplay between cellular targets of the IGF system and antineoplastic agents will facilitate the development of novel strategies for the prevention and treatment of cancer.

show abstract

Serum Insulin‐like Growth Factors, Insulin‐like Growth Factor‐binding Protein‐3, and Risk of Lung Cancer Death: A Case‐control Study Nested in the Japan Collaborative Cohort (JACC) Study

Cited by 42 publications

References 30 publications

Diabetes and the Risk of Lung Cancer

Diabetes and the Risk of Lung Cancer

Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies

Deregulation of the IGF axis in cancer: epidemiological evidence and potential therapeutic interventions.

Contact Info

Product

Resources

About